335 related articles for article (PubMed ID: 24444711)
1. Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit.
Zhu Z; Aref AR; Cohoon TJ; Barbie TU; Imamura Y; Yang S; Moody SE; Shen RR; Schinzel AC; Thai TC; Reibel JB; Tamayo P; Godfrey JT; Qian ZR; Page AN; Maciag K; Chan EM; Silkworth W; Labowsky MT; Rozhansky L; Mesirov JP; Gillanders WE; Ogino S; Hacohen N; Gaudet S; Eck MJ; Engelman JA; Corcoran RB; Wong KK; Hahn WC; Barbie DA
Cancer Discov; 2014 Apr; 4(4):452-65. PubMed ID: 24444711
[TBL] [Abstract][Full Text] [Related]
2. Targeting an IKBKE cytokine network impairs triple-negative breast cancer growth.
Barbie TU; Alexe G; Aref AR; Li S; Zhu Z; Zhang X; Imamura Y; Thai TC; Huang Y; Bowden M; Herndon J; Cohoon TJ; Fleming T; Tamayo P; Mesirov JP; Ogino S; Wong KK; Ellis MJ; Hahn WC; Barbie DA; Gillanders WE
J Clin Invest; 2014 Dec; 124(12):5411-23. PubMed ID: 25365225
[TBL] [Abstract][Full Text] [Related]
3. Autophagy Inhibition Dysregulates TBK1 Signaling and Promotes Pancreatic Inflammation.
Yang S; Imamura Y; Jenkins RW; Cañadas I; Kitajima S; Aref A; Brannon A; Oki E; Castoreno A; Zhu Z; Thai T; Reibel J; Qian Z; Ogino S; Wong KK; Baba H; Kimmelman AC; Pasca Di Magliano M; Barbie DA
Cancer Immunol Res; 2016 Jun; 4(6):520-30. PubMed ID: 27068336
[TBL] [Abstract][Full Text] [Related]
4. Overcoming Resistance to Dual Innate Immune and MEK Inhibition Downstream of KRAS.
Kitajima S; Asahina H; Chen T; Guo S; Quiceno LG; Cavanaugh JD; Merlino AA; Tange S; Terai H; Kim JW; Wang X; Zhou S; Xu M; Wang S; Zhu Z; Thai TC; Takahashi C; Wang Y; Neve R; Stinson S; Tamayo P; Watanabe H; Kirschmeier PT; Wong KK; Barbie DA
Cancer Cell; 2018 Sep; 34(3):439-452.e6. PubMed ID: 30205046
[TBL] [Abstract][Full Text] [Related]
5. The kinases IKBKE and TBK1 regulate MYC-dependent survival pathways through YB-1 in AML and are targets for therapy.
Liu S; Marneth AE; Alexe G; Walker SR; Gandler HI; Ye DQ; Labella K; Mathur R; Toniolo PA; Tillgren M; Gokhale PC; Barbie D; Mullally A; Stegmaier K; Frank DA
Blood Adv; 2018 Dec; 2(23):3428-3442. PubMed ID: 30504235
[TBL] [Abstract][Full Text] [Related]
6. Oncogenic KRAS-induced interleukin-8 overexpression promotes cell growth and migration and contributes to aggressive phenotypes of non-small cell lung cancer.
Sunaga N; Imai H; Shimizu K; Shames DS; Kakegawa S; Girard L; Sato M; Kaira K; Ishizuka T; Gazdar AF; Minna JD; Mori M
Int J Cancer; 2012 Apr; 130(8):1733-44. PubMed ID: 21544811
[TBL] [Abstract][Full Text] [Related]
7. Use of the pharmacological inhibitor BX795 to study the regulation and physiological roles of TBK1 and IkappaB kinase epsilon: a distinct upstream kinase mediates Ser-172 phosphorylation and activation.
Clark K; Plater L; Peggie M; Cohen P
J Biol Chem; 2009 May; 284(21):14136-46. PubMed ID: 19307177
[TBL] [Abstract][Full Text] [Related]
8. Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer.
Kitai H; Ebi H; Tomida S; Floros KV; Kotani H; Adachi Y; Oizumi S; Nishimura M; Faber AC; Yano S
Cancer Discov; 2016 Jul; 6(7):754-69. PubMed ID: 27154822
[TBL] [Abstract][Full Text] [Related]
9. ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism.
Peng DH; Kundu ST; Fradette JJ; Diao L; Tong P; Byers LA; Wang J; Canales JR; Villalobos PA; Mino B; Yang Y; Minelli R; Peoples MD; Bristow CA; Heffernan TP; Carugo A; Wistuba II; Gibbons DL
Sci Transl Med; 2019 Mar; 11(483):. PubMed ID: 30867319
[TBL] [Abstract][Full Text] [Related]
10. The comparison between dual inhibition of mTOR with MAPK and PI3K signaling pathways in KRAS mutant NSCLC cell lines.
Dogan Turacli I; Ozkan AC; Ekmekci A
Tumour Biol; 2015 Dec; 36(12):9339-45. PubMed ID: 26108998
[TBL] [Abstract][Full Text] [Related]
11. Targeting cytokine networks in KRAS-driven tumorigenesis.
Golay HG; Barbie DA
Expert Rev Anticancer Ther; 2014 Aug; 14(8):869-71. PubMed ID: 24928447
[TBL] [Abstract][Full Text] [Related]
12. Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors.
Sheppard KE; Cullinane C; Hannan KM; Wall M; Chan J; Barber F; Foo J; Cameron D; Neilsen A; Ng P; Ellul J; Kleinschmidt M; Kinross KM; Bowtell DD; Christensen JG; Hicks RJ; Johnstone RW; McArthur GA; Hannan RD; Phillips WA; Pearson RB
Eur J Cancer; 2013 Dec; 49(18):3936-44. PubMed ID: 24011934
[TBL] [Abstract][Full Text] [Related]
13. Enhanced Antitumor Activity of Cetuximab in Combination with the Jak Inhibitor CYT387 against Non-Small-Cell Lung Cancer with Various Genotypes.
Hu Y; Dong XZ; Liu X; Liu P; Chen YB
Mol Pharm; 2016 Feb; 13(2):689-97. PubMed ID: 26685983
[TBL] [Abstract][Full Text] [Related]
14. PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling.
Halilovic E; She QB; Ye Q; Pagliarini R; Sellers WR; Solit DB; Rosen N
Cancer Res; 2010 Sep; 70(17):6804-14. PubMed ID: 20699365
[TBL] [Abstract][Full Text] [Related]
15. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.
Park KS; Oh B; Lee MH; Nam KY; Jin HR; Yang H; Choi J; Kim SW; Lee DH
Cancer Lett; 2016 Mar; 372(1):75-81. PubMed ID: 26723875
[TBL] [Abstract][Full Text] [Related]
16. Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib.
Acquaviva J; Smith DL; Sang J; Friedland JC; He S; Sequeira M; Zhang C; Wada Y; Proia DA
Mol Cancer Ther; 2012 Dec; 11(12):2633-43. PubMed ID: 23012248
[TBL] [Abstract][Full Text] [Related]
17. IKKε and TBK1 in diffuse large B-cell lymphoma: A possible mechanism of action of an IKKε/TBK1 inhibitor to repress NF-κB and IL-10 signalling.
Carr M; Mamand S; Chapman KL; Perrior T; Wagner SD
J Cell Mol Med; 2020 Oct; 24(19):11573-11582. PubMed ID: 32858764
[TBL] [Abstract][Full Text] [Related]
18. Loss of p53 attenuates the contribution of IL-6 deletion on suppressed tumor progression and extended survival in Kras-driven murine lung cancer.
Tan X; Carretero J; Chen Z; Zhang J; Wang Y; Chen J; Li X; Ye H; Tang C; Cheng X; Hou N; Yang X; Wong KK
PLoS One; 2013; 8(11):e80885. PubMed ID: 24260500
[TBL] [Abstract][Full Text] [Related]
19. Activation of TBK1 and IKKvarepsilon kinases by vesicular stomatitis virus infection and the role of viral ribonucleoprotein in the development of interferon antiviral immunity.
tenOever BR; Sharma S; Zou W; Sun Q; Grandvaux N; Julkunen I; Hemmi H; Yamamoto M; Akira S; Yeh WC; Lin R; Hiscott J
J Virol; 2004 Oct; 78(19):10636-49. PubMed ID: 15367631
[TBL] [Abstract][Full Text] [Related]
20. The Ras/Raf/MEK/extracellular signal-regulated kinase pathway induces autocrine-paracrine growth inhibition via the leukemia inhibitory factor/JAK/STAT pathway.
Park JI; Strock CJ; Ball DW; Nelkin BD
Mol Cell Biol; 2003 Jan; 23(2):543-54. PubMed ID: 12509453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]